Morgan Stanley’s Scinai Immunotherapeutics SCNI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $33 | Hold |
58
| – | – | ﹤0.01% | 8073 |
|
|
2025
Q4 | $41 | Sell |
58
-187
| -76% | -$213 | ﹤0.01% | 7924 |
|
|
2025
Q3 | $310 | Sell |
245
-10
| -4% | -$17 | ﹤0.01% | 7553 |
|
|
2025
Q2 | $581 | Hold |
255
| – | – | ﹤0.01% | 7419 |
|
|
2025
Q1 | $687 | Hold |
255
| – | – | ﹤0.01% | 7334 |
|
|
2024
Q4 | $853 | Hold |
255
| – | – | ﹤0.01% | 7294 |
|
|
2024
Q3 | $880 | Hold |
255
| – | – | ﹤0.01% | 7238 |
|
|
2024
Q2 | $709 | Sell |
255
-3
| -1% | -$12 | ﹤0.01% | 7193 |
|
|
2024
Q1 | $1.34K | Sell |
258
-258
| -50% | -$1.33K | ﹤0.01% | 7138 |
|
|
2023
Q4 | $3.08K | Buy |
516
+288
| +126% | +$1.98K | ﹤0.01% | 7079 |
|
|
2023
Q3 | $1.99K | Buy |
228
+10
| +5% | +$128 | ﹤0.01% | 7133 |
|
|
2023
Q2 | $3.08K | Sell |
218
-8
| -4% | -$138 | ﹤0.01% | 7096 |
|
|
2023
Q1 | $4.88K | Sell |
226
-56
| -20% | -$1.38K | ﹤0.01% | 7055 |
|
|
2022
Q4 | $8.34K | Buy |
282
+56
| +25% | +$4.21K | ﹤0.01% | 6997 |
|
|
2022
Q3 | $17K | Sell |
226
-107
| -32% | -$12K | ﹤0.01% | 6864 |
|
|
2022
Q2 | $39K | Sell |
333
-143
| -30% | -$19.6K | ﹤0.01% | 6715 |
|
|
2022
Q1 | $79K | Buy |
476
+40
| +9% | +$5.81K | ﹤0.01% | 6464 |
|
|
2021
Q4 | $103K | Sell |
436
-19
| -4% | -$3.92K | ﹤0.01% | 6420 |
|
|
2021
Q3 | $100K | Sell |
455
-61
| -12% | -$15.7K | ﹤0.01% | 6379 |
|
|
2021
Q2 | $148K | Buy |
516
+101
| +24% | +$31.4K | ﹤0.01% | 6168 |
|
|
2021
Q1 | $157K | Sell |
415
-193
| -32% | -$84.3K | ﹤0.01% | 5793 |
|
|
2020
Q4 | $171K | Buy |
608
+121
| +25% | +$146K | ﹤0.01% | 5668 |
|
|
2020
Q3 | $1.9M | Buy |
487
+446
| +1,088% | +$1.71M | ﹤0.01% | 3696 |
|
|
2020
Q2 | $94K | Buy |
41
+39
| +1,950% | +$62.8K | ﹤0.01% | 5432 |
|
|
2020
Q1 | $2K | Sell |
2
-5
| -71% | -$4.43K | ﹤0.01% | 6399 |
|
|
2019
Q4 | $6K | Hold |
7
| – | – | ﹤0.01% | 6376 |
|
|
2019
Q3 | $4K | Hold |
7
| – | – | ﹤0.01% | 6402 |
|
|
2019
Q2 | $4K | Buy |
7
+2
| +40% | +$1.28K | ﹤0.01% | 6362 |
|
|
2019
Q1 | $3K | Hold |
5
| – | – | ﹤0.01% | 6409 |
|
|
2018
Q4 | $2K | Hold |
5
| – | – | ﹤0.01% | 6432 |
|
|
2018
Q3 | $3K | Hold |
5
| – | – | ﹤0.01% | 6517 |
|
|
2018
Q2 | $3K | Hold |
5
| – | – | ﹤0.01% | 6513 |
|
|
2018
Q1 | $2K | Sell |
5
-11
| -69% | -$6.87K | ﹤0.01% | 6505 |
|
|
2017
Q4 | $8K | Buy |
16
+11
| +220% | +$6.92K | ﹤0.01% | 6262 |
|
|
2017
Q3 | $3K | Buy |
5
+3
| +150% | +$2.46K | ﹤0.01% | 6366 |
|
|
2017
Q2 | $2K | Buy |
+2
| New | +$1.47K | ﹤0.01% | 6462 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 6633 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 6689 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 6774 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 6699 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 6729 |
|
Other funds holding SCNI
Morgan Stanley's SCNI Position: Q1 2026 in Review
Morgan Stanley held its Scinai Immunotherapeutics (SCNI) position steady in Q1 2026 at 58 shares worth $33. The position accounts for ﹤0.01% of the portfolio, ranked #8073.
Morgan Stanley first reported a position in SCNI in Q2 2017 and has held it in 36 quarters since. The position peaked at $1.9M in Q3 2020. 4 funds tracked by Wall St. Rank hold SCNI as of Q1 2026.
- Morgan Stanley held 58 shares of Scinai Immunotherapeutics worth $33 as of Q1 2026.
- Morgan Stanley left its Scinai Immunotherapeutics share count unchanged in Q1 2026.
- Scinai Immunotherapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #8073 holding.
- Morgan Stanley first reported a position in Scinai Immunotherapeutics in Q2 2017 and has held it in 36 quarters since.
- Morgan Stanley's Scinai Immunotherapeutics position peaked at $1.9M in Q3 2020.
- 4 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.